Loading clinical trials...
Loading clinical trials...
A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients With Neovascular Age-Related Macular Degeneration
Conditions
Interventions
REGN2176-3
Intravitreal Aflibercept Injection (IAI)
Locations
84
United States
Phoenix, Arizona, United States
Tucson, Arizona, United States
Arcadia, California, United States
Beverly Hills, California, United States
Irvine, California, United States
Mountain View, California, United States
Start Date
May 5, 2015
Primary Completion Date
August 17, 2016
Completion Date
April 3, 2017
Last Updated
October 26, 2020
NCT07308639
NCT06439576
NCT05562947
NCT05904028
NCT06213038
NCT06492863
Lead Sponsor
Regeneron Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions